Barbara Jungwirth is an experienced freelance journalist, writer, and translator who has been reporting on HIV for TheBody and TheBodyPro since 2002. Specializing in technical summaries of published and presented research on HIV and related topics, Barbara has been the primary author of TheBodyPro's "This Week in HIV Research" series since 2014.

Latest by Barbara Jungwirth

This Week in HIV Research: A Test of Resistance

May 16, 2019: The dwindling value of baseline genotype testing; severe insomnia and cardiovascular disease; cardiovascular risk stratified by sex among people over 50; the persistence of racial disparities among women diagnosed with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Better Serving the Underserved

May 9, 2019: HIV care retention and viral suppression among transgender women; heating opioid use equipment to curb HIV transmission; managing HIV outbreaks among people who are homeless; improving viral suppression among people who use substances.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Unexpected Outcomes

May 2, 2019: patient-centered care model improves viral suppression; subpar immune responses when baseline CD4 tops 500; when CD4 plummets despite viral suppression; vaccination, immunoglobulin, and hepatitis A exposure.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Disparities Drive the Epidemic

April 25, 2019: stigma and viral load among African-American women; U.S. HIV incidence sans racial disparities; the care continuum is failing young MSM; a moment of reckoning regarding HIV among U.S. youth.

By Barbara Jungwirth and Myles Helfand

Why Do Study Participants Misreport Their HIV Status?

A new study demonstrates the phenomenon, but experts say more research needs to determine why it occurs -- and what researchers can do differently to reduce it.

By Barbara Jungwirth

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: HIV Is Not an Obstacle

April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Fentanyl Smooths the Path for HIV

April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

By Barbara Jungwirth and Myles Helfand